Advertisement

Regulatory Framework for Biosimilars

  • Vinod P. ShahEmail author
  • Daan J. A. Crommelin
Chapter

Abstract

A “generic” version of a biopharmaceutical may be introduced after patent expiration of the innovator’s product. However, the generic paradigm as it has developed for low molecular weight actives over the years cannot be used for biopharmaceuticals. In the European Union and the US regulatory systems, the term “biosimilar” was coined for copies of brand name, innovator biopharmaceuticals. Different than for small molecule generic versions, in most cases, comparative clinical testing of the biosimilar product must include a robust evaluation of safety and confirmation of efficacy in appropriate patient populations. This chapter discusses the two practices that evolved in the USA and European Union for the development of the biosimilar drug products.

Keywords

EMA FDA Biosimilars Nonproprietary naming 

References

  1. Boone HN, van der Kuy H, Scott M, Mairs J, Krämer I, Vulto A, Janknegt R (2013) How to select a biosimilar. Eur J Hosp Pharm 20:275–228CrossRefGoogle Scholar
  2. Crommelin DJA, Storm G, Verrijk R, de Leede L, Jiskoot W, Hennink WE (2003) Shifting paradigms: biopharmaceuticals versus low molecular weight drugs. Int J Pharm 266:3–16CrossRefGoogle Scholar
  3. Kraemer I, Tredree R, Vulto A (2008) Points to consider in the evaluation of biopharmaceuticals. EJHP Practice 14:73–76Google Scholar
  4. QuintilesIMS (2017) The Impact of Biosimilar Competition in Europe. http://www.medicinesforeurope.com/wp-content/uploads/2017/05/IMS-Biosimilar-2017_V9.pdf

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.VPS Consulting, LLCNorth PotomacUSA
  2. 2.Department of Pharmaceutics, Utrecht Institute for Pharmaceutical SciencesUtrecht UniversityUtrechtThe Netherlands

Personalised recommendations